Since then, several other ADCs have been approved for the treatment of cancer including brentuximab vedotin for Hodgkin lymphoma[4], trastuzumab emtansine for breast cancer[5], trastuzumab deruxtecan for breast cancer[6] (recently approved for any HER2-positive solid cancer[7]), loncastuximab tesirine for diffuse large B-cell lymphoma[8], enfortumab vedotin for urothelial cancers[9] and mirvetuximab soravtansine for cisplatin-resistant ovarian cancers[10]. This evidence concerns the gene ERBB2 and breast carcinoma.